Sector News

Roche names new pharma research head

March 8, 2018
Life sciences

Roche Holding AG said Thursday that John Reed, head of pharma research and early development, has decided to leave the company and will be replaced by William Pao.

Mr. Pao is currently global head of the oncology discovery and translational area at the research and development department and will assume his new role on April 2, Roche said. He will also become a member of the company’s enlarged corporate executive committee.

“Since joining Roche in 2014, William has been instrumental in the build-up of cancer immunotherapy and molecular targeted therapies,” said Chief Executive Severin Schwan, on the appointment.

By Alberto Declaux

Source: MarketWatch

comments closed

Related News

December 10, 2023

Brain waves found in sleep shown to protect against epileptic activity

Life sciences

Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.

December 10, 2023

Rousselot’s soft gel capsule stabilizing technology awarded USPTO patent

Life sciences

StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.

December 10, 2023

Roche to acquire obesity drug maker Carmot

Life sciences

In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

How can we help you?

We're easy to reach